The complete list of business models in the synthetic biology market

Download our beautiful pitch about the synthetic biology market

A quick summary table

Metric	Value
Number of distinct synthetic biology business models mapped	20
Average scalability score across synthetic biology models	6.25 / 10
Highest scalability score (Biotech R&D SaaS)	9 / 10
Share of models rated High capital intensity	75% (15 of 20)
Models with Low or Medium capital intensity	Software, tools, and services only
Dominant primary buyer across top 10 models	Enterprise (B2B)
Best gross margin potential in synthetic biology	SaaS (score: 9)
Weakest margin segment	Commodity protein supply (score: 4)
Most common revenue model in top 10	Subscription or usage-based
Most common sales motion in bottom half	Partnerships
Defensibility score range across all models	5 to 8
Consumer-facing models ranked in the top half	0 of 4
Avg scalability, top 5 vs bottom 5 models	7.6 vs 5.4
Recommended investor entry point	B2B workflows, infrastructure, specialty ingredients

All the business models in the synthetic biology market

Here is a table that maps the main business models in the synthetic biology market, highlighting how they differ in scalability, margins, defensibility, capital intensity, and monetization approach.

Key insights about business models in the synthetic biology market

A few words about our methodology

This table maps the main business models used by startups in the synthetic biology market.

To build it, we first analyzed the leading companies in the synthetic biology market and examined how each one actually generates revenue.

We then grouped similar approaches into clear business model categories. The goal was to capture meaningful differences across the synthetic biology landscape without creating an overwhelming number of models.

Each synthetic biology business model is evaluated across four structural dimensions: scalability, margin potential, defensibility, and capital intensity.

Scalability measures how easily the model can grow without proportional increases in cost. Margin potential reflects the long-term gross margin typically achievable once the model reaches maturity.

Defensibility captures how sustainable the competitive advantage can be over time, considering factors like switching costs, network effects, or proprietary biological data.

Capital intensity indicates how much upfront investment is usually required to build and scale the model, which in synthetic biology often includes fermentation infrastructure, manufacturing scale-up, or regulatory approval costs.

For scalability, margin potential, and defensibility, scores range from 0 to 10. Lower scores indicate structural limitations, while scores above 7 generally signal strong economic potential.

These scores are not precise forecasts. They reflect the typical economics we observe across companies using that model in the synthetic biology market.

This framework is part of the broader research behind our report covering the synthetic biology market, where we analyze the ecosystem in much more detail.

If you want to better understand the ecosystem, you can also check our ranking of startups with the most fundraising in the synthetic biology market and the list of the startups with the biggest valuations in the synthetic biology market.

If you want more detail about our business model analysis or about a specific company in the synthetic biology market, feel free to contact us. We will gladly explain.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.